10 Foods To Reduce Blood Sugar Levels And Stop Diabetes

10 Foods To Reduce Blood Sugar Levels and Stop Diabetes

10 Foods To Reduce Blood Sugar Levels and Stop Diabetes
10 Foods To Reduce Blood Sugar Levels and Stop Diabetes
Blood Sugar Levels or Diabetes is a disease that can gradually affect your entire system and almost every organ in your body including your kidneys, eyes, heart and more.
Paying too much attention to your diet can make a big difference in whether you develop the disease or experience complications from it. In fact, one of the major factors behind the development of type 2 diabetes, along with many other chronic and degenerative diseases, is a poor diet.
Making some smart dietary choices can prevent or help control type 2 diabetes. Some superfoods can control diabetes by stabilizing or even lowering blood sugar levels when eaten on a regular basis in appropriate portions.
Even if you already take diabetes medications, it is essential to understand that what you eat and drink can greatly affect the way you manage the disease.
Several components in cinnamon promote glucose metabolism and reduce cholesterol. Studies have shown that in people with diabetes; only half a teaspoon of cinnamon powder per day can significantly decrease fasting blood glucose levels and increase insulin sensitivity.
There are many ways to add cinnamon to your diet. You can sprinkle some in your coffee, stir it in the morning oatmeal, or add it to chicken or fish dishes. You can also soak a medium-sized cinnamon stick in hot water to make a refreshing cup of cinnamon tea.
Sweet potatoes are a starchy vegetable that contains the beta-carotene antioxidant along with vitamin A, vitamin Continue reading

Rate this article

Total 1 ratings

Meet the 2017 Diabetes Educator of the Year: Davida Kruger

Meet the 2017 Diabetes Educator of the Year: Davida Kruger
Written by Mike Hoskins on August 4, 2017
Earlier this summer when the American Diabetes Association named its diabetes educator of the year, the honor fell to Davida Kruger in Detroit, who's been helping to shape diabetes care since the early 1980s.
Kruger has spent her career as a nurse practitioner (NP) at Detroit's Henry Ford Hospital working with Dr. Fred Whitehouse -- a "Historic Endo for the Ages " who once worked with the famous Dr. Elliot Joslin himself (!) -- and she's divided her time between the clinical practice and research. She was influential in the landmark DCCT study, has authored countless articles and books including the Diabetes Travel Guide in 2000, and overall has helped her profession keep pace with new diabetes technology and treatments as they hit the market.
As it happens, Kruger represents a small and under-represented portion of the 20,000 credentialed CDEs in this country, as only about 4% of them are NPs, who also have prescribing power like physicians. With the 2017 American Association of Diabetes Educators (AADE) annual meeting kicking off today in Indianapolis, we thought it was a perfect time to share her story here at the 'Mine.
A Chat with Award-Winning CDE Davida Kruger
DM) First off, congrats on the ADA recognition for your work. How did it feel getting that honor?
It was very humbling. Ive been in this position for 35 years and you do it for all the right reasons, for people with diabetes. You stay because youre just enjoying yourself too much to leave. Every time yo Continue reading

How pancreatic tumors could help to fight diabetes

How pancreatic tumors could help to fight diabetes
New research may change how we think about treatment options for diabetes.
A new study analyzes rare tumorsin which insulin-producing beta cells are produced in excess in order to find a "genetic recipe" for regenerating these cells. And thefindingsmight change the current therapeutic practices for treating diabetes.
Beta cells play a crucial role in the development of diabetes . These tiny cells found in our pancreas produce insulin , and a loss of beta cells is known to be a cause of type 1 diabetes .
Additionally, recent studies have shown that beta cells also play a crucial role in the development of type 2 diabetes . For instance, a study thatMedical News Today reported on found that the release of pro-inflammatory proteins kills off insulin-producing beta cells in the early stages of type 2 diabetes.
But the "problem" with beta cells, medically speaking, is that they replicate in early childhood but cease to proliferate after that.
New research, however, carried out by scientists at the Icahn School of Medicine at Mount Sinai in New York City, NY, uncovers a "genomic recipe" for regenerating these key cells.
The study was led by Dr. Andrew Stewart, the director of the Diabetes, Obesity, and Metabolism Institute at the Icahn School of Medicine, and the findings were published in the journal Nature Communications.
For the new research, Dr. Stewart and team analyzed a very rare type of benign tumor called insulinomas. These are "pancreatic beta cell adenomas" that secrete too much of the hormone insulin.
The t Continue reading

Gestational diabetes: 'I was misdiagnosed by my doctor' - Kidspot

On the day I was booked in for my three-hour glucose tolerance test I woke feeling like death. Already two and a half weeks into battling a severe flu you know the pee-yourself-coughing kind juggling a toddler and severe sleep deprivation due to the constant coughing and blocked sinuses, I knew I was about to endure the longest three hours of my life. With the drink down the hatch, and only the first of three blood samples taken, I already had the sense all was not right. I was far more affected physically than the last time and needed to lie down immediately to keep me from fainting.
I managed to keep the drink down and had blood drawn two more times. I left relieved it was over, but instinctively knowing this was not the end of the saga.
The following Monday, I receive a call from my obstetricians office. I am on the set of a photoshoot and busy instructing the photographer where to set up, briefing the hair and makeup artist and getting the looks I will style on the model ready. I answer my phone and its the obstetricians secretary. We exchange hellos and then she says, you have gestational diabetes.
I am completely taken by surprise, and was left speechless as she tells me she is booking me in to see an endocrinologist ASAP and they will be in touch to let me know about the diet I need to start on straight away and the apparatus I will need to buy to test my blood daily at multiple times. We hang up and I stand shell-shocked, tears flow as I ring my husband and tell him the news.
Then I think about it, I was so sick the day I had the test, could that have skewed Continue reading

Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment

Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment
Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment
Peptide immunotherapy offers a more nuanced approach that may reduce the risk for adverse effects in persons with type 1 diabetes.
Type 1 diabetes is characterized by the autoimmune destruction of pancreatic beta cells, leading to progressively decreasing insulin secretion. As beta cells die, hyperglycemia becomes more persistent, and most persons with type 1 diabetes have chronic hyperglycemia and often suffer from complications such as nephropathy and retinopathy. At present, treatment for type 1 diabetes targets hyperglycemia, but does not affect the underlying autoimmune processes.1
Immunomodulatory treatment, or immunotherapy, seeks to influence the immunological pathways that mediate beta cell destruction.1 "In the field of type 1 diabetes, we've been actively searching for ways to induce disease remission so that we can limit beta cell death, preserve endogenous insulin secretion, and limit the need for insulin injections," Carmella Evans-Molina, MD, PhD, from the Center for Diabetes and Metabolic Diseases at Indiana University in Indianapolis, told Endocrinology Advisor.
Although more than 25 years has been spent investigating immunotherapy for type 1 diabetes, no agent has proven to be effective at inducing remission in type 1 diabetes with an acceptable safety profile. Advances in the understanding of autoimmune conditions have led to the development of antigen-specific immunotherapy (ASI) and a subset of ASI known as pep Continue reading